Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy

  • Technology appraisal guidance
  • TA374
  • Published: 
Download guidance (PDF)

6 Review of guidance

6.1 The guidance on these technologies will be considered for review by the Guidance Executive 3 years after final publication. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
December 2015